$NKTR
Nektar Therapeutics Stock $nktr

$nktr Overview Financials Valuation SEC Filings Company Website

2019 Q4 Form 10-Q Financial Statement

#000090670919000010 Filed on November 07, 2019

Income Statement

Concept	2019 Q4	2019 Q3	2018 Q3
Revenue	$33.86M	$29.22M	$27.76M
YoY Change	-14.98%	5.24%	-81.85%
Cost Of Revenue	$5.989M	$4.927M	$4.783M
YoY Change	-19.73%	3.01%	-15.7%
Gross Profit	$27.87M	$24.29M	$22.98M
YoY Change	-13.88%	5.71%	-84.39%
Gross Profit Margin	82.31%	83.14%	82.77%
Selling, General & Admin	$27.10M	$24.00M	$18.70M
YoY Change	13.87%	28.34%	54.55%
% of Gross Profit	97.23%	98.8%	81.38%
Research & Development	$110.4M	$99.05M	$102.9M
YoY Change	1.36%	-3.74%	56.58%
% of Gross Profit	395.97%	407.76%	447.78%
Depreciation & Amortization	$3.600M	$3.500M	$2.700M
YoY Change	16.13%	29.63%	-28.95%
% of Gross Profit	12.92%	14.41%	11.75%
Operating Expenses	$110.4M	$99.05M	$102.9M
YoY Change	1.36%	-3.74%	56.58%
Operating Profit	-$109.6M	-$98.74M	-$98.63M
YoY Change	9.32%	0.11%	-241.95%
Interest Expense	-$2.200M	$5.425M	$5.442M
YoY Change	-1200.0%	-0.31%	-164.79%
% of Operating Profit
Other Income/Expense, Net		$254.0K	$1.591M
YoY Change		-84.04%
Pretax Income	-$111.9M	-$98.49M	-$97.04M
YoY Change	11.79%	1.49%	-258.83%
Income Tax	$1.500M	$99.00K	-$900.0K
% Of Pretax Income
Net Earnings	-$112.2M	-$98.59M	-$96.14M
YoY Change	14.21%	2.54%	-257.95%
Net Earnings / Revenue	-331.24%	-337.41%	-346.31%
Basic Earnings Per Share	-$0.64	-$0.56	-$0.56
Diluted Earnings Per Share	-$0.64	-$0.56	-$0.56
COMMON SHARES
Basic Shares Outstanding	175.9M shares	175.4M shares	172.7M shares
Diluted Shares Outstanding		175.4M shares	172.7M shares

Balance Sheet

Concept	2019 Q4	2019 Q3	2018 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.325B	$1.496B	$1.420B
YoY Change	-0.79%	5.3%	302.84%
Cash & Equivalents	$96.36M	$81.22M	$222.3M
Short-Term Investments	$1.228B	$1.414B	$1.198B
Other Short-Term Assets	$15.39M	$15.21M	$12.54M
YoY Change	-27.74%	21.31%	-5.71%
Inventory	$12.67M	$13.72M	$13.30M
Prepaid Expenses
Receivables	$36.80M	$41.21M	$31.90M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$1.422B	$1.579B	$1.505B
YoY Change	-1.12%	4.89%	293.2%
LONG-TERM ASSETS
Property, Plant & Equipment	$65.67M	$64.61M	$44.90M
YoY Change	34.42%	43.91%	-28.04%
Goodwill	$76.50M	$76.50M
YoY Change	0.0%
Intangibles
YoY Change
Long-Term Investments	$279.1M	$231.1M	$619.1M
YoY Change	-52.12%	-62.67%	938.76%
Other Assets	$344.0K	$2.385M	$3.400M
YoY Change	-91.89%	-29.85%	325.0%
Total Long-Term Assets	$555.8M	$509.5M	$743.9M
YoY Change	-21.99%	-31.52%	273.27%
TOTAL ASSETS
Total Short-Term Assets	$1.422B	$1.579B	$1.505B
Total Long-Term Assets	$555.8M	$509.5M	$743.9M
Total Assets	$1.977B	$2.088B	$2.249B
YoY Change	-8.04%	-7.15%	286.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$19.23M	$21.96M	$7.500M
YoY Change	228.56%	192.84%	-12.79%
Accrued Expenses	$79.50M	$95.00M	$78.30M
YoY Change	28.64%	21.33%	97.73%
Deferred Revenue	$5.517M	$8.400M	$15.68M
YoY Change	-60.29%	-46.41%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$248.7M
YoY Change
Total Short-Term Liabilities	$353.9M	$125.4M	$108.1M
YoY Change	331.57%	15.96%	16.86%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$248.3M	$246.5M
YoY Change	-100.0%	0.73%	0.69%
Other Long-Term Liabilities	$768.0K	$643.0K	$104.4M
YoY Change	-92.31%	-99.38%	-34.99%
Total Long-Term Liabilities	$768.0K	$643.0K	$350.9M
YoY Change	-92.31%	-99.82%	-13.44%
TOTAL LIABILITIES
Total Short-Term Liabilities	$353.9M	$125.4M	$108.1M
Total Long-Term Liabilities	$768.0K	$643.0K	$350.9M
Total Liabilities	$572.0M	$599.6M	$459.0M
YoY Change	32.22%	30.63%	-7.81%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.865B	-$1.751B
YoY Change	30.94%
Common Stock	$3.271B	$3.241B
YoY Change	3.91%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.405B	$1.489B	$1.790B
YoY Change
Total Liabilities & Shareholders Equity	$1.977B	$2.088B	$2.249B
YoY Change	-8.04%	-7.15%	286.38%

Cashflow Statement

Concept	2019 Q4	2019 Q3	2018 Q3
OPERATING ACTIVITIES
Net Income	-$112.2M	-$98.59M	-$96.14M
YoY Change	14.21%	2.54%	-257.95%
Depreciation, Depletion And Amortization	$3.600M	$3.500M	$2.700M
YoY Change	16.13%	29.63%	-28.95%
Cash From Operating Activities	-$125.2M	-$68.70M	-$71.40M
YoY Change	6.46%	-3.78%	-176.69%
INVESTING ACTIVITIES
Capital Expenditures	-$3.700M	-$5.300M	-$1.900M
YoY Change	-56.98%	178.95%	90.0%
Acquisitions
YoY Change
Other Investing Activities	$139.2M	$63.60M	-$619.4M
YoY Change	44.7%	-110.27%	677.16%
Cash From Investing Activities	$135.5M	$58.20M	-$621.3M
YoY Change	54.68%	-109.37%	669.89%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	5.000M	6.200M	3.900M
YoY Change	85.19%	58.97%	-58.95%
NET CHANGE
Cash From Operating Activities	-125.2M	-68.70M	-71.40M
Cash From Investing Activities	135.5M	58.20M	-621.3M
Cash From Financing Activities	5.000M	6.200M	3.900M
Net Change In Cash	15.30M	-4.300M	-688.8M
YoY Change	-156.04%	-99.38%	-3245.21%
FREE CASH FLOW
Cash From Operating Activities	-$125.2M	-$68.70M	-$71.40M
Capital Expenditures	-$3.700M	-$5.300M	-$1.900M
Free Cash Flow	-$121.5M	-$63.40M	-$69.50M
YoY Change	11.47%	-8.78%	-173.86%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
	dei	Entity Central Index Key EntityCentralIndexKey	0000906709
	nktr	Debt Investment Maturity Term DebtInvestmentMaturityTerm	P1Y
	nktr	Debt Investment Maximum Maturity Period DebtInvestmentMaximumMaturityPeriod	P2Y
CY2018Q4	nktr	Preferred Stock Share Designated PreferredStockShareDesignated	0	shares
CY2019Q3	nktr	Preferred Stock Share Designated PreferredStockShareDesignated	0	shares
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2019Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	173530000	shares
CY2019Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	175786000	shares
CY2018Q3	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2018Q3	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0	USD
CY2019Q3	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0	USD
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2019Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2019Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q3	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	0	USD
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2019-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	0-24006
	dei	Entity Registrant Name EntityRegistrantName	NEKTAR THERAPEUTICS
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	94-3134940
	dei	Entity Address Address Line1 EntityAddressAddressLine1	455 Mission Bay Boulevard South
	dei	Entity Address City Or Town EntityAddressCityOrTown	San Francisco
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94158
	dei	City Area Code CityAreaCode	415
	dei	Local Phone Number LocalPhoneNumber	482-5300
	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value
	dei	Trading Symbol TradingSymbol	NKTR
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2019Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	175922206	shares
CY2019Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	81224000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	194905000	USD
CY2019Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	1414448000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	1140445000	USD
CY2019Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	41205000	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	43213000	USD
CY2019Q3	us-gaap	Inventory Net InventoryNet	13720000	USD
CY2018Q4	us-gaap	Inventory Net InventoryNet	11381000	USD
CY2019Q3	nktr	Advance Payments To Contract Manufacturers AdvancePaymentsToContractManufacturers	13015000	USD
CY2018Q4	nktr	Advance Payments To Contract Manufacturers AdvancePaymentsToContractManufacturers	26450000	USD
CY2019Q3	us-gaap	Other Assets Current OtherAssetsCurrent	15212000	USD
CY2018Q4	us-gaap	Other Assets Current OtherAssetsCurrent	21293000	USD
CY2019Q3	us-gaap	Assets Current AssetsCurrent	1578824000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	1437687000	USD
CY2019Q3	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	231082000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	582889000	USD
CY2019Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	64614000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	48851000	USD
CY2019Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	134888000	USD
CY2018Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0	USD
CY2019Q3	us-gaap	Goodwill Goodwill	76501000	USD
CY2018Q4	us-gaap	Goodwill Goodwill	76501000	USD
CY2019Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2385000	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4244000	USD
CY2019Q3	us-gaap	Assets Assets	2088294000	USD
CY2018Q4	us-gaap	Assets Assets	2150172000	USD
CY2019Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	21963000	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5854000	USD
CY2019Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	23101000	USD
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	9937000	USD
CY2019Q3	nktr	Accrued Clinical Trial Expenses Current AccruedClinicalTrialExpensesCurrent	38338000	USD
CY2018Q4	nktr	Accrued Clinical Trial Expenses Current AccruedClinicalTrialExpensesCurrent	14700000	USD
CY2019Q3	nktr	Accrued Contract Manufacturing Expense Current AccruedContractManufacturingExpenseCurrent	8646000	USD
CY2018Q4	nktr	Accrued Contract Manufacturing Expense Current AccruedContractManufacturingExpenseCurrent	23841000	USD
CY2019Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	11394000	USD
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	9580000	USD
CY2019Q3	us-gaap	Interest Payable Current InterestPayableCurrent	4198000	USD
CY2018Q4	us-gaap	Interest Payable Current InterestPayableCurrent	4198000	USD
CY2019Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	9318000	USD
CY2018Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0	USD
CY2019Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	8392000	USD
CY2018Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	13892000	USD
CY2019Q3	us-gaap	Liabilities Current LiabilitiesCurrent	125350000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	82002000	USD
CY2019Q3	us-gaap	Senior Long Term Notes SeniorLongTermNotes	248257000	USD
CY2018Q4	us-gaap	Senior Long Term Notes SeniorLongTermNotes	246950000	USD
CY2019Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	145099000	USD
CY2018Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	USD
CY2019Q3	nktr	Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts	73455000	USD
CY2018Q4	nktr	Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts	82911000	USD
CY2019Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	6779000	USD
CY2018Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	10744000	USD
CY2019Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	643000	USD
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	9990000	USD
CY2019Q3	us-gaap	Liabilities Liabilities	599583000	USD
CY2018Q4	us-gaap	Liabilities Liabilities	432597000	USD
CY2019Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q3	us-gaap	Common Stock Value CommonStockValue	17000	USD
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	17000	USD
CY2019Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	3241160000	USD
CY2018Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	3147925000	USD
CY2019Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1186000	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-6316000	USD
CY2019Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1751280000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1424051000	USD
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	1488711000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	1717575000	USD
CY2019Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2088294000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2150172000	USD
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	29218000	USD
CY2018Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	27762000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	80755000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1153497000	USD
CY2019Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4927000	USD
CY2018Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4783000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	15385000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	16951000	USD
CY2019Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	99048000	USD
CY2018Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	102895000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	324197000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	290653000	USD
CY2019Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	23983000	USD
CY2018Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	18718000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	71570000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	57666000	USD
CY2019Q3	us-gaap	Costs And Expenses CostsAndExpenses	127958000	USD
CY2018Q3	us-gaap	Costs And Expenses CostsAndExpenses	126396000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	411152000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	365270000	USD
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-98740000	USD
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-98634000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-330397000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	788227000	USD
CY2019Q3	us-gaap	Interest Expense InterestExpense	5425000	USD
CY2018Q3	us-gaap	Interest Expense InterestExpense	5442000	USD
	us-gaap	Interest Expense InterestExpense	15882000	USD
	us-gaap	Interest Expense InterestExpense	16167000	USD
CY2019Q3	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	5813000	USD
CY2018Q3	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	4814000	USD
	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	17853000	USD
	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	14808000	USD
CY2019Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	11492000	USD
CY2018Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	11847000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	35964000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	25523000	USD
CY2019Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	254000	USD
CY2018Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1591000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2229000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5452000	USD
CY2019Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-98486000	USD
CY2018Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-97043000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-328168000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	782775000	USD
CY2019Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	322000	USD
CY2018Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-900000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-939000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3250000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-98808000	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-96143000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-327229000	USD
	us-gaap	Net Income Loss NetIncomeLoss	779525000	USD
CY2019Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.56
CY2018Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.56
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.87
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	4.63
CY2019Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.56
CY2018Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.56
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.87
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	4.34
CY2019Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	175402000	shares
CY2018Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	172698000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	174609000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	168363000	shares
CY2019Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	175402000	shares
CY2018Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	172698000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	174609000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	179619000	shares
CY2019Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-99206000	USD
CY2018Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-97519000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-322099000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	776258000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	1717575000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	5463000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	25385000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	3600000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-118512000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	1633511000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	7103000	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	24522000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	1928000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-109909000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	1557155000	USD
CY2019Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	5882000	USD
CY2019Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	24880000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-398000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-98808000	USD
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	1488711000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	87828000	USD
CY2018Q1	us-gaap	Cumulative Effect On Retained Earnings Net Of Tax1 CumulativeEffectOnRetainedEarningsNetOfTax1	12577000	USD
CY2018Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	34406000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	19949000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-685000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-95792000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	58283000	USD
CY2018Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	790231000	USD
CY2018Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	20987000	USD
CY2018Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	20659000	USD
CY2018Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1206000	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	971460000	USD
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	1860414000	USD
CY2018Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	3940000	USD
CY2018Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	23287000	USD
CY2018Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1376000	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-96143000	USD
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	1790122000	USD
	us-gaap	Profit Loss ProfitLoss	-327229000	USD
	us-gaap	Profit Loss ProfitLoss	779525000	USD
	nktr	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	27585000	USD
	nktr	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	24337000	USD
	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	17853000	USD
	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	14808000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	74787000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	63895000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	9582000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	7799000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	10421000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	8136000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2008000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	16179000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2339000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2570000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-18127000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	22087000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	16109000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2611000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	13164000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	19659000	USD
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	10019000	USD
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	26603000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-9465000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-10931000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	11932000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	5104000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-203458000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	835764000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	1028883000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	1944178000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	1122902000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	467658000	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	0	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	11963000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	22614000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5552000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	2633000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	71405000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1467476000	USD
	nktr	Proceeds From Issuance Of Common Stock Net Of Issuance Costs ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts	0	USD
	nktr	Proceeds From Issuance Of Common Stock Net Of Issuance Costs ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts	790231000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	18449000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	59067000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	18449000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	849298000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-77000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-87000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-113681000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	217499000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	194905000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4762000	USD
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	81224000	USD
CY2018Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	222261000	USD
	us-gaap	Interest Paid Net InterestPaidNet	14229000	USD
	us-gaap	Interest Paid Net InterestPaidNet	14701000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	56025000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
CY2019Q3	nktr	Cash Restricted Cash Cash Equivalents And Available For Sale Investments CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments	1700000000	USD
CY2019Q3	us-gaap	Senior Notes SeniorNotes	250000000.0	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. Actual results could differ materially from those estimates and </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">assumptions. As appropriate, we assess our estimates each period, update them to reflect current information and generally recognize any changes in such estimates in the period first identified.</span></div>
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Significant Concentrations</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our customers are primarily pharmaceutical and biotechnology companies that are located in the U.S. and Europe and with whom we have multi-year arrangements. Our accounts receivable balance contains billed and unbilled trade receivables from product sales, milestones, other contingent payments and royalties, as well as reimbursable costs from collaborative research and development agreements. As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, our accounts receivable includes </span><span style="font-family:inherit;font-size:10pt;"><span>$27.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$24.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, for net expense reimbursements from our collaboration partner Bristol-Myers Squibb Company (BMS). </span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, our ability to develop and produce our drug candidates or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations.</span></div>
	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	1300000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	300000	USD
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.004
CY2019Q3	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2019Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	81224000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	194905000	USD
CY2019Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	1414448000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	1140445000	USD
CY2019Q3	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	231082000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	582889000	USD
CY2019Q3	nktr	Cash Restricted Cash Cash Equivalents And Available For Sale Investments CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments	1726754000	USD
CY2018Q4	nktr	Cash Restricted Cash Cash Equivalents And Available For Sale Investments CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments	1918239000	USD
CY2019Q3	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	0	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	12000000.0	USD
CY2019Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1646043000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1800011000	USD
CY2019Q3	us-gaap	Cash Cash	28166000	USD
CY2018Q4	us-gaap	Cash Cash	5812000	USD
CY2019Q3	nktr	Cash Restricted Cash Cash Equivalents And Available For Sale Investments CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments	1726754000	USD
CY2018Q4	nktr	Cash Restricted Cash Cash Equivalents And Available For Sale Investments CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments	1918239000	USD
CY2019Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1586000	USD
CY2018Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1846000	USD
CY2019Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	7961000	USD
CY2018Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	6403000	USD
CY2019Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	4173000	USD
CY2018Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	3132000	USD
CY2019Q3	us-gaap	Inventory Net InventoryNet	13720000	USD
CY2018Q4	us-gaap	Inventory Net InventoryNet	11381000	USD
CY2019Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	4116000	USD
CY2018Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	1927000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	10030000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	5651000	USD
CY2019Q3	us-gaap	Variable Lease Cost VariableLeaseCost	1485000	USD
CY2018Q3	us-gaap	Variable Lease Cost VariableLeaseCost	1096000	USD
	us-gaap	Variable Lease Cost VariableLeaseCost	4539000	USD
	us-gaap	Variable Lease Cost VariableLeaseCost	3371000	USD
CY2019Q3	us-gaap	Lease Cost LeaseCost	5601000	USD
CY2018Q3	us-gaap	Lease Cost LeaseCost	3023000	USD
	us-gaap	Lease Cost LeaseCost	14569000	USD
	us-gaap	Lease Cost LeaseCost	9022000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	5100000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	2400000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	15283000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	19026000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	19633000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	20257000	USD
CY2019Q3	nktr	Lessee Operating Lease Liability Payments Due Year Six LesseeOperatingLeaseLiabilityPaymentsDueYearSix	20899000	USD
CY2019Q3	nktr	Lessee Operating Lease Liability Payments Due After Year Six LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix	116881000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	214379000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	56621000	USD
CY2019Q3	nktr	Lessee Operating Lease Liability Tenant Improvement Reimbursements LesseeOperatingLeaseLiabilityTenantImprovementReimbursements	3341000	USD
CY2019Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	154417000	USD
CY2019Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	9318000	USD
CY2019Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	145099000	USD
CY2019Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P10Y3M18D
CY2019Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.059
	nktr	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	27600000	USD
	nktr	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	24300000	USD
	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	17900000	USD
	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	14800000	USD
	nktr	Estimated Annual Interest Rate Over Life Of Royalty Liability EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability	0.17
CY2017Q4	nktr	Estimated Annual Interest Rate Over Life Of Royalty Liability EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability	0.176
CY2017Q4	nktr	Prospective Interest Rate Percentage ProspectiveInterestRatePercentage	0.21
CY2018Q4	nktr	Estimated Annual Interest Rate Over Life Of Royalty Liability EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability	0.187
CY2018Q4	nktr	Prospective Interest Rate Percentage ProspectiveInterestRatePercentage	0.29
CY2019Q3	nktr	License Collaboration Other Revenue LicenseCollaborationOtherRevenue	3121000	USD
CY2018Q3	nktr	License Collaboration Other Revenue LicenseCollaborationOtherRevenue	4875000	USD
	nktr	License Collaboration Other Revenue LicenseCollaborationOtherRevenue	9860000	USD
	nktr	License Collaboration Other Revenue LicenseCollaborationOtherRevenue	1082848000	USD
CY2019Q3	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	20500000	USD
	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	56600000	USD
CY2018Q3	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	18600000	USD
	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	64200000	USD
CY2018Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	24636000	USD
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	9465000	USD
CY2019Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	15171000	USD
CY2019Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	8400000	USD
CY2019Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	6800000	USD
CY2019Q3	nktr	Potential Development And Regulatory Milestones PotentialDevelopmentAndRegulatoryMilestones	1700000000	USD
CY2019Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	24880000	USD
CY2018Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	23287000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	74787000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	63895000	USD
CY2019Q3	us-gaap	Stock Issued During Period Shares Share Based Compensation StockIssuedDuringPeriodSharesShareBasedCompensation	820000	shares
CY2018Q3	us-gaap	Stock Issued During Period Shares Share Based Compensation StockIssuedDuringPeriodSharesShareBasedCompensation	642000	shares
	us-gaap	Stock Issued During Period Shares Share Based Compensation StockIssuedDuringPeriodSharesShareBasedCompensation	2256000	shares
	us-gaap	Stock Issued During Period Shares Share Based Compensation StockIssuedDuringPeriodSharesShareBasedCompensation	5248000	shares
CY2018Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	17600000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	11300000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3200000	shares

Files In Submission

Name	View Source	Status
0000906709-19-000010-index-headers.html	Edgar Link	pending
0000906709-19-000010-index.html	Edgar Link	pending
0000906709-19-000010.txt	Edgar Link	pending
0000906709-19-000010-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nktr-20190930.xsd	Edgar Link	pending
nktr-20190930_cal.xml	Edgar Link	unprocessable
nktr-20190930_def.xml	Edgar Link	unprocessable
nktr-20190930_lab.xml	Edgar Link	unprocessable
nktr-20190930_pre.xml	Edgar Link	unprocessable
nktr2019-09x30x10q.htm	Edgar Link	pending
nktr2019-09x30x10q_htm.xml	Edgar Link	completed
nktr2019-09x30xexx101.htm	Edgar Link	pending
nktr2019-09x30xexx311.htm	Edgar Link	pending
nktr2019-09x30xexx312.htm	Edgar Link	pending
nktr2019-09x30xexx321.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NKTR
Nektar Therapeutics Stock $nktr

2019 Q4 Form 10-Q Financial Statement

#000090670919000010 Filed on November 07, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NKTR Nektar Therapeutics Stock $nktr

2019 Q4 Form 10-Q Financial Statement

#000090670919000010 Filed on November 07, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NKTR
Nektar Therapeutics Stock $nktr